This review highlights the interconnected roles of chronic low-grade inflammation, hyperinsulinemia, hyperandrogenism, and sympathetic nervous system dysregulation in the pathophysiology and cardiometabolic risk of PCOS.
Answers are grounded in this paper and cite their sources.
Suggests inflammation as therapeutic target in PCOS; leaves open whether interventions improve cardiometabolic outcomes.
Polycystic ovary syndrome (PCOS) has become increasingly common over recent years and is associated with reproductive features as well as cardiometabolic risk factors, including visceral obesity, dyslipidemia and impaired glucose homeostasis, and potentially cardiovascular disease. Emerging evidence suggests that these long-term metabolic effects are linked to a low-grade chronic inflammatory state with the triad of hyperinsulinemia, hyperandrogenism, and low-grade inflammation acting together in a vicious cycle in the pathophysiology of PCOS. Dysregulation of the sympathetic nervous system may also act as an important component, potentially creating a tetrad in the pathophysiology of PCOS. The aim of this review is to examine the role of chronic inflammation and the sympathetic nervous system in the development of obesity and PCOS and review potential therapeutic options to alleviate low-grade inflammation in this setting.
No takes yet. Share an insight, caveat, or question.
Shorakae et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: